Cargando…

Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia

The hepatitis C virus (HCV) causes both acute and chronic infection of the liver that can lead to liver cirrhosis, cancer, and liver failure. HCV is characterized by high genetic diversity and substantial variations in the prevalence of specific HCV genotypes throughout the world. Many effective reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimenov, Nikolay, Kostyushev, Dmitry, Komarova, Svetlana, Fomicheva, Anastasia, Urtikov, Alexander, Belaia, Olga, Umbetova, Karina, Darvina, Olga, Tsapkova, Natalia, Chulanov, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781887/
https://www.ncbi.nlm.nih.gov/pubmed/36558817
http://dx.doi.org/10.3390/pathogens11121482
_version_ 1784857184528498688
author Pimenov, Nikolay
Kostyushev, Dmitry
Komarova, Svetlana
Fomicheva, Anastasia
Urtikov, Alexander
Belaia, Olga
Umbetova, Karina
Darvina, Olga
Tsapkova, Natalia
Chulanov, Vladimir
author_facet Pimenov, Nikolay
Kostyushev, Dmitry
Komarova, Svetlana
Fomicheva, Anastasia
Urtikov, Alexander
Belaia, Olga
Umbetova, Karina
Darvina, Olga
Tsapkova, Natalia
Chulanov, Vladimir
author_sort Pimenov, Nikolay
collection PubMed
description The hepatitis C virus (HCV) causes both acute and chronic infection of the liver that can lead to liver cirrhosis, cancer, and liver failure. HCV is characterized by high genetic diversity and substantial variations in the prevalence of specific HCV genotypes throughout the world. Many effective regimens of direct-acting antivirals (DAAs), including pan-genotypic, can successfully treat HCV infection. Additionally, genotype-specific treatments for HCV are being actively employed in national plans for eliminating HCV infection around the world. The evaluation of HCV genotype prevalence in a given country is necessary for the successful implementation of the HCV elimination plans and for allocating financial resources to the DAAs which are the most effective against those specific HCV genotypes prevalent in a given country. Here, we analyzed HCV genotypes, subgenotypes, and recombinants in 10,107 serum samples collected in 2015–2017 from patients with chronic HCV infection living in all federal districts of Russia. This is the first and largest evaluation of HCV genotypes performed on samples from all territories of Russia, from its Central federal district to the Far East. Moreover, we have updated retrospective epidemiological analysis of chronic and acute HCV infection in Russia from 2001 to 2021. We demonstrate that the incidence of acute HCV (AHC) infection in Russia decreased from 16.7 cases per 100,000 people in 2001 to 0.6/100,000 in 2021. The number of cases of chronic HCV (CHC) infection also decreased from 29.5 to 16.4 per 100,000 people during this period. The HCV genotype analysis indicated that HCV genotype 1 dominates in Russia (53.6%), while genotypes 3 and 2 were detected in 35.4% and 7.8% of patients, respectively. These proportions are virtually identical in all regions of Russia except for the Far East, where HCV genotype 2 was detected in only 1% of the samples. HCV genotypes 1 and 2 are more widespread in women, and HCV genotype 3 in men. Genotype 3 was the most prevalent in 31–40-year-olds (44.9%), and genotype 1 was most prevalent in those over 70 years of age (72.2%). HCV genotype 2 was predominant among HCV-infected persons older than 40 years. Discriminating between HCV genotype 2 and recombinant RF1_2k/1b, which are frequently misclassified, is important for successful antiviral treatment. For the first time, we demonstrate, here, countrywide prevalence of HCV RF1_2k/1b in different regions of Russia. HCV RF1_2k/1b makes up 3.2% of HCV genotypes, reaching 30% among samples classified as genotype 2 by some commercial genotyping tests. The highest proportion of HCV RF1_2k/1b was detected in the North-West (60%), Southern (41.6%), and Central (31.6%) federal districts; its frequency in the Far Eastern and North Caucasus districts was ~14.3%. HCV RF1_2k/1b, and it was not detected in the Volga, Ural, or Siberian districts. To conclude, this is the first and most complete evaluation of HCV epidemiology and genotype/subgenotype distribution in Russia.
format Online
Article
Text
id pubmed-9781887
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97818872022-12-24 Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia Pimenov, Nikolay Kostyushev, Dmitry Komarova, Svetlana Fomicheva, Anastasia Urtikov, Alexander Belaia, Olga Umbetova, Karina Darvina, Olga Tsapkova, Natalia Chulanov, Vladimir Pathogens Article The hepatitis C virus (HCV) causes both acute and chronic infection of the liver that can lead to liver cirrhosis, cancer, and liver failure. HCV is characterized by high genetic diversity and substantial variations in the prevalence of specific HCV genotypes throughout the world. Many effective regimens of direct-acting antivirals (DAAs), including pan-genotypic, can successfully treat HCV infection. Additionally, genotype-specific treatments for HCV are being actively employed in national plans for eliminating HCV infection around the world. The evaluation of HCV genotype prevalence in a given country is necessary for the successful implementation of the HCV elimination plans and for allocating financial resources to the DAAs which are the most effective against those specific HCV genotypes prevalent in a given country. Here, we analyzed HCV genotypes, subgenotypes, and recombinants in 10,107 serum samples collected in 2015–2017 from patients with chronic HCV infection living in all federal districts of Russia. This is the first and largest evaluation of HCV genotypes performed on samples from all territories of Russia, from its Central federal district to the Far East. Moreover, we have updated retrospective epidemiological analysis of chronic and acute HCV infection in Russia from 2001 to 2021. We demonstrate that the incidence of acute HCV (AHC) infection in Russia decreased from 16.7 cases per 100,000 people in 2001 to 0.6/100,000 in 2021. The number of cases of chronic HCV (CHC) infection also decreased from 29.5 to 16.4 per 100,000 people during this period. The HCV genotype analysis indicated that HCV genotype 1 dominates in Russia (53.6%), while genotypes 3 and 2 were detected in 35.4% and 7.8% of patients, respectively. These proportions are virtually identical in all regions of Russia except for the Far East, where HCV genotype 2 was detected in only 1% of the samples. HCV genotypes 1 and 2 are more widespread in women, and HCV genotype 3 in men. Genotype 3 was the most prevalent in 31–40-year-olds (44.9%), and genotype 1 was most prevalent in those over 70 years of age (72.2%). HCV genotype 2 was predominant among HCV-infected persons older than 40 years. Discriminating between HCV genotype 2 and recombinant RF1_2k/1b, which are frequently misclassified, is important for successful antiviral treatment. For the first time, we demonstrate, here, countrywide prevalence of HCV RF1_2k/1b in different regions of Russia. HCV RF1_2k/1b makes up 3.2% of HCV genotypes, reaching 30% among samples classified as genotype 2 by some commercial genotyping tests. The highest proportion of HCV RF1_2k/1b was detected in the North-West (60%), Southern (41.6%), and Central (31.6%) federal districts; its frequency in the Far Eastern and North Caucasus districts was ~14.3%. HCV RF1_2k/1b, and it was not detected in the Volga, Ural, or Siberian districts. To conclude, this is the first and most complete evaluation of HCV epidemiology and genotype/subgenotype distribution in Russia. MDPI 2022-12-06 /pmc/articles/PMC9781887/ /pubmed/36558817 http://dx.doi.org/10.3390/pathogens11121482 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pimenov, Nikolay
Kostyushev, Dmitry
Komarova, Svetlana
Fomicheva, Anastasia
Urtikov, Alexander
Belaia, Olga
Umbetova, Karina
Darvina, Olga
Tsapkova, Natalia
Chulanov, Vladimir
Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia
title Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia
title_full Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia
title_fullStr Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia
title_full_unstemmed Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia
title_short Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia
title_sort epidemiology and genotype distribution of hepatitis c virus in russia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781887/
https://www.ncbi.nlm.nih.gov/pubmed/36558817
http://dx.doi.org/10.3390/pathogens11121482
work_keys_str_mv AT pimenovnikolay epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT kostyushevdmitry epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT komarovasvetlana epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT fomichevaanastasia epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT urtikovalexander epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT belaiaolga epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT umbetovakarina epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT darvinaolga epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT tsapkovanatalia epidemiologyandgenotypedistributionofhepatitiscvirusinrussia
AT chulanovvladimir epidemiologyandgenotypedistributionofhepatitiscvirusinrussia